Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Q1 2017 Earnings Presentation

18 slides from Avadel Pharmaceuticals's earnings presentation, May 11, 2017

  1. Slide 1: Q1 2017 Earnings Conference Call

    Q1 2017 Earnings Conference Call May 9th, 2017

  2. Slide 2: Safe Harbor

    2 Safe Harbor This presentation may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "assume," "believe," "expect," "estima

  3. Slide 3: Strategy Execution: 1Q 2017 Overview

    3 Strategy Execution: 1Q 2016 Overview • Market Dynamics: Hospital Products • Akovaz® • Bloxiverz® • Vazculep® • REST-ON Phase III Trial Update • Non-GAAP Financial Results • GAAP Financial Results • Product Sales • Cash Flow • 2017 Guidance

  4. Slide 4: Market Dynamics: Akovaz Ephedrine Market

    4 Market Dynamics: Akovaz® Ephedrine Market Volume / Year IMS Data Repackaging Market • Three approved products in 1Q 2017 • Total vials per year ~7.5M • ~5M vials captured by IMS data • ~2.5M vials to private repackaging market • Akovaz IMS share during 1Q 2017 was approximately 15% - 20% • Total m

  5. Slide 5: Market Dynamics: Bloxiverz

    5 Market Dynamics: Bloxiverz® 0 200000 400000 600000 800000 1000000 1200000 1400000 1Q 2016 2Q 2016 3Q 2016 4Q 2016 1Q 2017 Neuromuscular Blockade Reversal Market Volume Neostigmine Sugammadex • IMS Data tracks neuromuscular blockade market at ~5M vials per year • Neostigmine declined as a percent o

  6. Slide 6: Market Dynamics: Vazculep

    6 Market Dynamics: Vazculep® 0% 20% 40% 60% 80% 100% 1mL 5mL 10mL Market Share by Vial Size Avadel Other • Vazculep held approximately 40% of the 1mL market volume during 1Q 2017 • Vazculep 5mL & 10mL have been sole source since approval in 2014 • Relatively consistent share and revenue over the las

  7. Slide 7: Progress to Date: REST-ON Phase III Trial

    7 Progress to Date REST-ON Phase III Trial • SPA in place with FDA • Upfront agreement from FDA on powering and trial design • Clinical sites actively recruiting patients • USA • Europe • Canada • Enrollment completion goal of year end 2017

  8. Slide 8: Pediatric Products & Business Development

    8 Pediatric Products & Business Development • Karbinal ER • TRx up 26% quarter / quarter • TRx up 67% year / year • Launched Flexichamber® for use with metered dose inhalers for the treatment of asthma launched $179.2M in Cash & Marketable Securities - Actively looking for acquisitions to add new re

  9. Slide 9: Non-GAAP Financial Results

    9 Non-GAAP Financial Results *Reconciliations from GAAP to Non-GAAP can be found in the appendix (in 000s) 03/31/17 12/31/16 03/31/16 Sales 52,507$ 43,085$ 36,216$ Cost of products and services sold 3,856 3,610 3,143 Research and development expenses 7,206 13,476 5,388 Selling, general and admin exp

  10. Slide 10: GAAP Financial Results

    10 GAAP Financial Results (in 000s) 03/31/17 12/31/16 03/31/16 Sales 52,507$ 43,085$ 36,216$ Cost of products and services sold 3,902 2,591 3,906 Research and development expenses 7,206 13,476 5,388 Selling, general and admin expenses 11,812 10,688 9,461 Intangible asset amortization 564 2,970 3,514

  11. Slide 11: Product Sales

    11 Product Sales in $000's Q1 2016 Q4 2016 Q1 2016 Q1 2017 vs. Q4 2016 Q1 2017 vs. Q1 2016 Bloxiverz 13,902$ 16,938$ 24,747$ (3,036)$ (10,845)$ Vazculep 10,179 10,629 9,406 (450) 773 Akovaz 25,638 11,263 - 14,375 25,638 Other 2,038 3,534 1,200 (1,496) 838 Total product sales and services 51,757$ 42,

  12. Slide 12: Cash Flow Summary

    12 Cash Flow Summary in $000's 2017 2016 TOTAL Cash and Marketable Securities Beginning Balance 154,195$ 144,802$ Operating Cash Flows (excl tax and earnout payments) 33,477 22,497 Earnout/Royalty Payments (8,613) (9,106) Capital Spending (334) (460) FX 108 403 Other 381 1,818 Change in Total 25,019

  13. Slide 13: Full Year 2017 Guidance - Updated

    13 Full Year 2017 Guidance - Updated UPDATED PREVIOUS Sales $170M - $185M $170M - $200M R&D Expense $40M - $50M $40M - $50M SG&A Expense ~$40M ~$40M Income Tax Rate 60% - 70% 70% - 80% Diluted EPS (Adjusted) $0.30 - $0.45 $0.20 - $0.35 2017 Guidance

  14. Slide 14: Question & Answer

    14 Question & Answer

  15. Slide 15: Appendix

    15 APPENDIX

  16. Slide 16: GAAP to Non-GAAP Reconciliations: Three Months Ended March 31, 2017

    16 GAAP to NON-GAAP Reconciliations Three Months Ended March 31, 2017: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Restructuring impacts Purchase accounting adjustments - FSC Contingent related party payable fair value remeasurements Contingent relat

  17. Slide 17: GAAP to Non-GAAP Reconciliations: Three Months Ended December 31, 2016

    17 GAAP to NON-GAAP Reconciliations Three Months Ended December 31, 2016: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Cross-border merger impacts Purchase accounting adjustments - FSC Contingent related party payable fair value remeasurements Conting

  18. Slide 18: GAAP to Non-GAAP Reconciliations: Three Months Ended March 31, 2016

    18 GAAP to NON-GAAP Reconciliations Three Months Ended March 31, 2016: (in thousands - USD$) Include GAAP Intangible asset amortization Foreign exchange (gain)/loss Purchase accounting adjustments - FSC Contingent related party payable fair value remeasurements Contingent related party payable paid/

Avadel Pharmaceuticals — Q1 2017 Earnings Presentation on 6ix